Discovery and characterization of a hydroxypyridone-3-carboxamide analog as an antiviral lead against orthopoxviruses
Antimicrobial Agents and Chemotherapy · 2026
DOI: 10.1128/aac.01922-25 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2026. Verfasst von Anil Pant und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Veterinary Pathobiology, College of Veterinary Medicine & Biomedical Sciences, Texas A&M University, College Station, Texas, USA. Hauptthemen laut MEDLINE: Antiviral Agents, Orthopoxvirus, Pyridones. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
Orthopoxviruses remain a persistent global health concern due to the ongoing circulation of mpox, the possibility of the re-emergence of smallpox, and the threats posed by many poxviruses that infect animals and/or humans. The limited availability of antiviral drugs, the unproven efficacy in humans, and the emergence of resistant mutants underscore the need for new and better therapeutics. In this study, we identify and characterize ZW-2038, a hydroxypyridone-3-carboxamide analog, as an antiviral compound against vaccinia virus (VACV), monkeypox virus (MPXV), and cowpox virus (CPXV). Discovered through a focused in-house small-molecule screen, ZW-2038 exhibited low micromolar potency and high selectivity in primary human fibroblasts. The compound also reduced viral replication under physiomimetic conditions, including human and monkey intestinal organoids (enteroids) and ex vivo mouse lung tissue models. Mechanistically, ZW-2038 suppresses VACV DNA replication and downstream post-replicative gene expression, albeit without inhibiting MPXV resolvase (Mpr) in vitro . These findings, along with in vitro safety profiling and mice pharmacokinetics studies, characterize ZW-2038 as a promising, yet suboptimal antiviral lead against orthopoxviruses, warranting future development.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Veterinary Pathobiology, College of Veterinary Medicine & Biomedical Sciences, Texas A&M University, College Station, Texas, USA.
- Center for Drug Design, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota, USA.
ORCID-Profile: Anil Pant, Ajit Jagtap, Jacob P Mahoney, Tibor Farkas, Zhengqiang Wang, Zhilong Yang
Förderung
- NIAID NIH HHS
- NIH HHS
- National Institutes of Health
Zitieren
APA
Pant, A., Jagtap, A., Xie, J., Brahim Belhaouari, D., Xie, W., Mahoney, J. P., Dsouza, L., Wang, Z., Aboezz, Z. R., Farkas, T., Wang, Z., & Yang, Z. (2026). Discovery and characterization of a hydroxypyridone-3-carboxamide analog as an antiviral lead against orthopoxviruses. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.01922-25
Vancouver
Pant A, Jagtap A, Xie J, Brahim Belhaouari D, Xie W, Mahoney JP, et al. Discovery and characterization of a hydroxypyridone-3-carboxamide analog as an antiviral lead against orthopoxviruses. Antimicrobial Agents and Chemotherapy. 2026. doi:10.1128/aac.01922-25
BibTeX
@article{Pant2026,
author = {Pant, Anil and Jagtap, Ajit and Xie, Jiashu and Brahim Belhaouari, Djamal and Xie, Wei and Mahoney, Jacob P and Dsouza, Lara and Wang, Ziyue and Aboezz, Zeinab R and Farkas, Tibor and Wang, Zhengqiang and Yang, Zhilong},
title = {Discovery and characterization of a hydroxypyridone-3-carboxamide analog as an antiviral lead against orthopoxviruses},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2026},
doi = {10.1128/aac.01922-25}
}
EUVIMED